This is a preprint.
Quantitative CT Scoring for Local COPD Severity
- PMID: 40297437
- PMCID: PMC12036413
- DOI: 10.1101/2025.04.09.25324951
Quantitative CT Scoring for Local COPD Severity
Update in
-
Elastic parametric response mapping: quantitative CT scoring for local COPD severity.Thorax. 2026 Jan 12:thorax-2025-223755. doi: 10.1136/thorax-2025-223755. Online ahead of print. Thorax. 2026. PMID: 41526163
Abstract
Chronic obstructive pulmonary disease (COPD) is complex, and its course is difficult to predict due to its diverse pathophysiology. Small airway disease (SAD), a key component of COPD and potential target for emerging therapeutics, may be reversible in mild COPD, but left unchecked, may worsen, leading to airway loss and emphysema. The dual nature of SAD complicates clinical management of COPD patients, necessitating more accurate monitoring methods. To meet this need, we developed elastic Parametric Response Mapping (ePRM), a tiered scoring system that classifies local lung volumes by the degree of PRM-derived SAD, normal, and emphysematous tissue. In individuals with or at risk for COPD, we demonstrate that chest CT ePRM can categorize local lung tissue into distinct tiers of disease severity that distinguish between tissue characterized by early reversible SAD and progressive destruction. This level of characterization is crucial to developing personalized treatment strategies for COPD.
Keywords: chronic obstructive pulmonary disease; computed tomography of the chest; elastic principal graph; emphysema; machine learning; parametric response mapping; small airways disease.
Conflict of interest statement
WWL reports personal fees from Konica Minolta and Continuing Education Alliance. BAH and CJG are co-inventors and patent holders of tPRM, which the University of Michigan has licensed to 4D Medical. CJG is co-inventor and patent holder of PRM, which the University of Michigan has licensed to 4D Medical. CRH is employed by and has stock options in 4D Medical, Inc. MKH reports personal fees from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Cipla, Chiesi, Novartis, Pulmonx, Teva, Verona, Merck, Mylan, Sanofi, DevPro, Aerogen, Polarian, Regeneron, Amgen, UpToDate, Altesa Biopharma, Medscape, NACE, MDBriefcase and Integrity. She has received either in kind research support or funds paid to the institution from the NIH, Novartis, Sunovion, Nuvaira, Sanofi, AstraZeneca, Boehringer Ingelheim, Gala Therapeutics, Biodesix, the COPD Foundation and the American Lung Association. She has participated in Data Safety Monitoring Boards for Novartis and Medtronic with funds paid to the institution. She has received stock options from Meissa Vaccines and Altesa Biopharma. SR, AN, AJB, EAK, SG, FJM, SM, EMM, ANG, and AZ report no conflicts of interest.
Figures
References
-
- Duffy S., Weir M., and Criner G.J., The complex challenge of chronic obstructive pulmonary disease. Lancet Respir Med, 2015. 3(12): p. 917–9. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources